Incidence of interstitial pneumonitis in breast cancer patients treated with pegylated liposomal doxorubicin

[1] Jasra S(2018)Anthracycline use for early stage breast cancer in the modern era: a review Curr Treat Options Oncol 19 30-89

[2] Anampa J(2014)Doxorubicin, DNA torsion, and chromatin dynamics Biochim Biophys Acta 1845 84-1257

[3] Yang F(2012)Interstitial pneumonitis induced by pegylated liposomal doxorubicin in a patient with recurrent ovarian cancer Med Oncol. 29 1255-224

[4] Teves SS(2014)Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer Anticancer Drugs 25 219-449

[5] Kemp CJ(2004)Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer Ann Oncol 15 440-1478

[6] Henikoff S(2012)Fatal pneumonitis after treatment with pegylated liposomal doxorubicin in a patient with metastatic breast cancer in complete remission Med Oncol 29 1477-70

[7] Inaba K(2010)Interstitial pneumonitis after treatment with bevacizumab and pegylated liposomal doxorubicin in a patient with metastatic breast cancer Chemotherapy 56 69-378

[8] Arimoto T(2000)Acute interstitial pneumonitis. Case series and review of the literature Medcine (Baltimore) 79 369-1836

[9] Hoya M(2016)Drug induced interstitial lung disease in oncology phase I trials Cancer Sci 107 1830-1875

[10] Kawana K(2008)Incidence of interstitial pneumonitis among breast cancer patients: a 10-year Danish population-based cohort study Br J Cancer 98 1870-315

[1] Jasra S(2018)Anthracycline use for early stage breast cancer in the modern era: a review Curr Treat Options Oncol 19 30-89

[2] Anampa J(2014)Doxorubicin, DNA torsion, and chromatin dynamics Biochim Biophys Acta 1845 84-1257

[3] Yang F(2012)Interstitial pneumonitis induced by pegylated liposomal doxorubicin in a patient with recurrent ovarian cancer Med Oncol. 29 1255-224

[4] Teves SS(2014)Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer Anticancer Drugs 25 219-449

[5] Kemp CJ(2004)Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer Ann Oncol 15 440-1478

[6] Henikoff S(2012)Fatal pneumonitis after treatment with pegylated liposomal doxorubicin in a patient with metastatic breast cancer in complete remission Med Oncol 29 1477-70

[7] Inaba K(2010)Interstitial pneumonitis after treatment with bevacizumab and pegylated liposomal doxorubicin in a patient with metastatic breast cancer Chemotherapy 56 69-378

[8] Arimoto T(2000)Acute interstitial pneumonitis. Case series and review of the literature Medcine (Baltimore) 79 369-1836

[9] Hoya M(2016)Drug induced interstitial lung disease in oncology phase I trials Cancer Sci 107 1830-1875

[10] Kawana K(2008)Incidence of interstitial pneumonitis among breast cancer patients: a 10-year Danish population-based cohort study Br J Cancer 98 1870-315